Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...
Le leader français de l’industrie pharmaceutique envisage de se séparer de sa filiale de médicaments sans ordonnance d’antidouleur. Deux offres lui sont parvenues de fonds ...
In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.
Victimes de la Dépakine : l’État avance 65 millions à Sanofi et se substitue au laboratoire fautif
Dépakine : douze ans après, Sanofi condamné à indemniser la lanceuse d’alerte Marine Martin Contacté par l’Humanité, Sanofi confirme qu’il continuera à agir de la sorte, estimant ...
Après Sanofi, au tour de l'industriel allemand de la santé Merck d'annoncer son intérêt pour des unités de production ...
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.
Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business. The ...
(AOF) - Sanofi (-0,39% à 103,28 ... serait prêt à prendre une décision définitive dans les jours à venir. La cession annoncée en octobre 2023 viserait à créer "deux entités, chacune ...
As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...
CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. The grant comes from the ...
After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback